INT79736

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 12
Disease Relevance 2.31
Pain Relevance 4.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Ntrk1) endosome (Ntrk1) aging (Ntrk1)
plasma membrane (Ntrk1) cytoplasm (Ntrk1)
Anatomy Link Frequency
neuronal 1
NuGr 1
CHO 1
Ntrk1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Nerve growth factor 12 100.00 Very High Very High Very High
opioid receptor 3 99.66 Very High Very High Very High
Somatostatin 16 99.40 Very High Very High Very High
neurotrophin 3 10 98.88 Very High Very High Very High
Cannabinoid receptor 1 98.80 Very High Very High Very High
Pain 13 98.24 Very High Very High Very High
agonist 11 96.56 Very High Very High Very High
Enkephalin 1 95.60 Very High Very High Very High
Glutamate 7 95.48 Very High Very High Very High
Neurotransmitter 1 94.84 High High
Disease Link Frequency Relevance Heat
Pain 11 98.24 Very High Very High Very High
Cancer 8 97.88 Very High Very High Very High
Apoptosis 61 97.76 Very High Very High Very High
Death 30 96.00 Very High Very High Very High
Reprotox - General 1 1 89.52 High High
Peripheral Neuropathy 5 83.76 Quite High
Inflammatory Pain 1 82.92 Quite High
Spinal Cord Injury 58 80.20 Quite High
Neuropathic Pain 1 76.88 Quite High
INFLAMMATION 31 75.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These effects are due to suppression of the levels of the 100 kDa prolactin receptor or of the high affinity NGF receptors (trk), are mediated by CB(1)-like cannabinoid receptors, and are enhanced by other CFADs.
Negative_regulation (suppression) of trk associated with cannabinoid receptor and nerve growth factor
1) Confidence 0.57 Published 2000 Journal Prostaglandins Other Lipid Mediat. Section Abstract Doc Link 10785541 Disease Relevance 0.51 Pain Relevance 0.54
Decreased Trk mRNA may result in decreased NT activity in the NuGr.
Negative_regulation (Decreased) of Trk in NuGr
2) Confidence 0.41 Published 2004 Journal Exp. Neurol. Section Abstract Doc Link 15144880 Disease Relevance 0.39 Pain Relevance 0.52
There is the simultaneous down-regulation of genes for a number of neurotrophic factor receptors (Gfra3, Gfra2, Gfra1, Ntrk1, and Adcyap1r1).
Negative_regulation (number) of Ntrk1
3) Confidence 0.35 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC3001741 Disease Relevance 0.32 Pain Relevance 0.04
Even though our present study revealed a down-regulation of three receptors of the GDNF family [78,79] and Ntrk1, genes for other growth factor receptors that did not demonstrate a change in expression may provide clues as to which neurotrophic agents might prove useful for LDPT axonal regeneration.
Negative_regulation (regulation) of Ntrk1
4) Confidence 0.35 Published 2010 Journal BMC Neurosci Section Body Doc Link PMC3001741 Disease Relevance 0.26 Pain Relevance 0.07
In contrast, the stimulatory effects were completely blocked by K-252a, an inhibitor of tyrosine kinase (Trk) receptors, whereas the less active analog K-252b was ineffective.
Negative_regulation (inhibitor) of Trk
5) Confidence 0.21 Published 1999 Journal Endocrinology Section Abstract Doc Link 9927323 Disease Relevance 0 Pain Relevance 0.73
OBJECTIVE: This paper reviews those patent applications since 2002 claiming small-molecule inhibitors of Trk receptor kinases.
Negative_regulation (inhibitors) of Trk
6) Confidence 0.16 Published 2009 Journal Expert Opin Ther Pat Section Body Doc Link 19441906 Disease Relevance 0.19 Pain Relevance 0
Thus, inhibitors of Trk receptor kinases might provide targeted treatments for pain and cancer.
Negative_regulation (inhibitors) of Trk associated with pain and cancer
7) Confidence 0.16 Published 2009 Journal Expert Opin Ther Pat Section Abstract Doc Link 19441906 Disease Relevance 0.54 Pain Relevance 0.27
Furthermore, exogenous BDNF was sufficient to increase ubiquitination of synaptic proteins, whereas scavenging endogenous BDNF or inhibiting Trk kinase activity prevented the ubiquitination of synaptic proteins induced by chronic elevation of neuronal activity.
Negative_regulation (inhibiting) of Trk kinase in neuronal
8) Confidence 0.14 Published 2008 Journal J. Biol. Chem. Section Abstract Doc Link 18474605 Disease Relevance 0 Pain Relevance 0.17
In CHO cells expressing delta-opioid receptor, the inhibitory effect of TRK-820 on cAMP accumulation was very weak.
Negative_regulation (effect) of TRK-820 in CHO associated with opioid receptor
9) Confidence 0.10 Published 1999 Journal Eur. J. Pharmacol. Section Abstract Doc Link 10440101 Disease Relevance 0 Pain Relevance 0.90
Exogenous BDNF reversed changes in synaptic proteins induced by chronic activity blockade, while inhibiting Trk kinase activity or depleting endogenous BDNF abolished the concentration changes induced by chronic activity elevation.
Negative_regulation (inhibiting) of Trk kinase
10) Confidence 0.10 Published 2008 Journal J. Biol. Chem. Section Abstract Doc Link 18474605 Disease Relevance 0 Pain Relevance 0.14
In the case of the BDNF receptor, a kinase inhibitor of Trk type receptors was used, K-252a (100 nM), which partially blocked the effect of NMDA, but not that of BzATP.
Negative_regulation (inhibitor) of Trk
11) Confidence 0.09 Published 2010 Journal Cell Mol Life Sci Section Body Doc Link PMC2858808 Disease Relevance 0.11 Pain Relevance 0.07
BDNF or NT-3 induction of somatostatin release was inhibited by the Trk inhibitors K-252a and genistein, whereas K-252b, a less effective inhibitor, had no effect.
Negative_regulation (inhibitors) of Trk associated with neurotrophin 3 and somatostatin
12) Confidence 0.02 Published 2001 Journal Neuroendocrinology Section Abstract Doc Link 11435757 Disease Relevance 0 Pain Relevance 0.67

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox